October 16, 2018
Value of the oversold should follow the upside spiral
You can lead a horse to water but you can't make him drink' is a proverb which means that you can show investors an opportunity but can’t force them to take it.
Pre-open indications: BUY
In compiling my indication signals, I draw on logic, historical precedents, specific knowledge of the sector and its practices as to lessons learned. It’s important for investors to identify and determine which indication is actual performance based.
October 14, 2018
By Steve Brozak, DMH – President, WBB Securities LLC
Friday, Corium International Inc. announced its shares were being purchased at a 50% premium to their closing price along with a Contingent Value Right by a private investment firm focused on healthcare and life sciences, Gurnet Point Capital.
To read the entire article at Forbes, please click:
According to the Alzheimer’s Association, the number of Americans 65 and older diagnosed with Alzheimer’s rose from 4.7 million in 2010 to 5.5 million in 2018. The U.S. Alzheimer’s population is expected to hit nearly 14 million Americans by 2050.
October 15, 2018
Sector equities fell as indexes failed to bounce-back from last week's collapse as the oversold are still trying to find bottoms
Pre-open indications: 2 HITs and 0 MISS
The sector is being driven by the same theme - until we get some optimism, the path of least resistance is lower.
RMi puts the facts into evidence for the metrics to speak; my motto, “Never leave an investor uninformed”!
October 14, 2018
Shares of VSTM closed down $0.58 or -9.31%% to $5.65 due to its selling millions worth of (unsecured) convertible notes due 2048; that might seem like a low interest rate to be paying for such a long term, but the note holders can convert the notes into 139.5771 shares for every $1,000 principal amount of the notes they own.
October 10, 2018
BOLD closed down -$6.88or -18.73% to $29.83 after Tuesday's +$0.37 to $36.70. With a 52 week change of +32.63% with ... ... 37.33 M shares outstanding and a float of 29.2 M shares – issue a -8.43% or 1.97 M share short ratio.
October 3, 2018
Q3/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies. The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
